ESMO Open shared on X:
“HER2DX in early-stage HER2-positive BC: a review of clinical utility in ESMO Open. Genomic-clinical test with providing prognostic relapse risk score, pCR score, ERBB2 mRNA expression score.
Potential support for individualized Tx discussion.”
Title: HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility
Authors: S.M. Tolaney, N. Tung, A.C. Wolff, A. DeMichele, J.M. Cejalvo, O. Martínez-Sáez, T. Pascual, A.G. Waks, K. Nozawa, H. Iwata, M. Martín, E. Ciruelos, N. Harbeck, L.A. Carey, J. Cortés, A. Llombart, P. Sharma, and G. Curigliano.
Hope Rugo, Director of the Breast Oncology Clinical Trials Program, shared ESMO Open’s post, adding:
“The next step in personalization of the intensity of therapy avoiding the cookbook approach.”
You can also read: Insights From I-SPY2 Trial: Dual Immune Checkpoint Blockade Shows Promise in High-Risk ERBB2-Negative Early Breast Cancer
